Featured image
Biotechnology Companies

Cyprotex

Cyprotex is a biotechnology company located in Macclesfield, England. They specialize in IT and e-commerce solutions for the biotechnology industry.

Introduction to Cyprotex

Cyprotex is a biotechnology company that was founded in 1999 in Macclesfield, England. The company specializes in providing in vitro ADME-Tox services to the pharmaceutical and biotech industries. Cyprotex's unique selling point is that they integrate their in vitro ADME-Tox services with their proprietary software, which allows for more efficient and accurate drug development.

Services & Products

Cyprotex offers a variety of in vitro ADME-Tox services, including metabolic stability, permeability, transporter, inhibition, induction, and toxicity studies. They also provide a range of in silico services, such as QSAR modeling and PBPK modeling.

Location

Cyprotex is located in Alderley Park, a science and technology park in Macclesfield, England. The area is home to many other biotechnology companies and research facilities. Customers can expect to experience a vibrant and innovative atmosphere in the area. The closest public transportation options to Cyprotex are the Alderley Park Train Station (0.8 miles), the AstraZeneca Bus Stop (0.9 miles), and the Wilmslow Train Station (3.5 miles).

Benefits

Customers should choose Cyprotex because of their unique integration of in vitro ADME-Tox services with their proprietary software. This allows for more efficient and accurate drug development, which can save time and money for customers. Additionally, Cyprotex has a strong reputation in the industry for providing high-quality services and delivering results quickly.

Good to know

Customers should be aware that Cyprotex's services are focused specifically on in vitro ADME-Tox studies, and they do not provide other types of preclinical testing services. Additionally, Cyprotex does not offer clinical trial services.

Reviews

Customers have praised Cyprotex for their high-quality services and fast turnaround times. They have also noted that the integration of in vitro ADME-Tox services with proprietary software has been very helpful in their drug development processes.

FAQ

What specific areas of biotechnology does your company specialize in?

We specialize in ADME-Tox, which stands for Absorption, Distribution, Metabolism, Excretion and Toxicity. This includes in vitro ADME services, predictive toxicology and in silico modelling.

Can you provide examples of successful biotech projects your company has completed?

We've worked on a range of successful projects, including drug discovery and development, toxicity testing and environmental fate testing. Our clients have included pharmaceutical companies, government agencies and academic institutions.

What kind of expertise and experience do your employees have in biotechnology?

Our employees have a range of expertise and experience in biotechnology, including pharmacology, toxicology, chemistry and computer science. Many of our scientists hold PhDs and have extensive experience in the industry.

How does your company ensure regulatory compliance in biotech research and development?

We work closely with regulatory agencies such as the FDA and EMA to ensure that our research and development processes meet all necessary guidelines and regulations. We also have a dedicated team that focuses on quality assurance and compliance.

What measures does your company take to protect intellectual property in the biotech industry?

We take intellectual property protection very seriously and have a number of measures in place to safeguard our clients' valuable information. This includes confidentiality agreements, secure data storage and restricted access to sensitive information. We also work with our clients to ensure that they have appropriate patent protection in place.

Reviews

  • Rachel Fernandez

    26-05-2020
  • Radha Ramachandran

    Cyprotex is the current market leader in ADME-Tox and Bioscience outsourced service provider to the pharmaceutical, cosmetics/personal care and chemical industries

    26-05-2018